Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
58 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Evotec AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Evotec AG - Product Pipeline Review - 2014', provides an overview of the Evotec AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Evotec AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Evotec AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Evotec AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Evotec AG's pipeline products Reasons to buy - Evaluate Evotec AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Evotec AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Evotec AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Evotec AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Evotec AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Evotec AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 6 Evotec AG Snapshot 7 Evotec AG Overview 7 Key Information 7 Key Facts 7 Evotec AG - Research and Development Overview 8 Key Therapeutic Areas 8 Evotec AG - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 Pipeline Products - Out-Licensed Products 15 Out-Licensed Products/Combination Treatment Modalities 16 Evotec AG - Pipeline Products Glance 17 Evotec AG - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 Evotec AG - Early Stage Pipeline Products 19 Preclinical Products/Combination Treatment Modalities 19 Discovery Products/Combination Treatment Modalities 20 Evotec AG - Drug Profiles 21 EVT-201 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 EVT-401 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Drug To Target KDM For Oncology 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Drugs for Endometriosis 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 EVT-501 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Insulin Sensitizer 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Small Molecule to Antagonize B1 for Pain 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Small Molecule to Antagonize P2X3 and P2X2/3 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecule to Inhibit PDE10a for Schizophrenia and Psychosis 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Small Molecules for Inflammation 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Small Molecules for Neurodegeneration 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Undisclosed Molecule for Pain 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Drug For Anemia 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Drug for Kidney Diseases 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Drug for Solid Tumor and Leukemia 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Drugs for Glioblastoma Multiforme 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Drugs for TargetEEM 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Drugs to Inhibit FGFR3 for Cancer 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Drugs to Inhibit Isocitrate Dehydrogenase for Cancer 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Induced Pluripotent Stem Cells For Amyotrophic Lateral Sclerosis 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecule For Alzheimers Disease 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecule to Inhibit BACE-1 for Alzheimers Disease 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecule to Inhibit PGB for Bacterial Infections 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Small Molecule To Inhibit Serine Racemase For Neurology 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Small Molecules for Chronic Kidney Disease 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Small Molecules for Huntington Disease 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Small Molecules for Multiple Sclerosis 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Small Molecules to Inhibit Kv1.3 for Autoimmune Disorders 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Evotec AG - Pipeline Analysis 49 Evotec AG - Pipeline Products by Route of Administration 49 Evotec AG - Pipeline Products by Molecule Type 50 Evotec AG - Recent Pipeline Updates 51 Evotec AG - Dormant Projects 52 Evotec AG - Discontinued Pipeline Products 53 Discontinued Pipeline Product Profiles 53 EVT-301 53 RG-1577 53 REN-1654 53 REN-213 53 REN-850 53 Evotec AG - Company Statement 54 Evotec AG - Locations And Subsidiaries 55 Head Office 55 Other Locations & Subsidiaries 55 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 58 Disclaimer 58
List of Tables Evotec AG, Key Information 7 Evotec AG, Key Facts 7 Evotec AG - Pipeline by Indication, 2014 9 Evotec AG - Pipeline by Stage of Development, 2014 11 Evotec AG - Monotherapy Products in Pipeline, 2014 12 Evotec AG - Partnered Products in Pipeline, 2014 13 Evotec AG - Partnered Products/ Combination Treatment Modalities, 2014 14 Evotec AG - Out-Licensed Products in Pipeline, 2014 15 Evotec AG - Out-Licensed Products/ Combination Treatment Modalities, 2014 16 Evotec AG - Phase II, 2014 17 Evotec AG - Phase I, 2014 18 Evotec AG - Preclinical, 2014 19 Evotec AG - Discovery, 2014 20 Evotec AG - Pipeline by Route of Administration, 2014 49 Evotec AG - Pipeline by Molecule Type, 2014 50 Evotec AG - Recent Pipeline Updates, 2014 51 Evotec AG - Dormant Developmental Projects,2014 52 Evotec AG - Discontinued Pipeline Products, 2014 53 Evotec AG, Subsidiaries 55
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.